233 related articles for article (PubMed ID: 15830134)
1. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
Rha SY; Moon YH; Jeung HC; Kim YT; Sohn JH; Yang WI; Suh CO; Kim GE; Roh JK; Chung HC
Breast Cancer Res Treat; 2005 Apr; 90(3):215-21. PubMed ID: 15830134
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Murad AM
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
[TBL] [Abstract][Full Text] [Related]
3. High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Vici P; Capomolla E; Foggi P; Carpano S; Conti F; Paoletti G; Cauchi C; Giacinti L; Leonetti C; Giannarelli D; Lopez M
J Exp Clin Cancer Res; 2006 Mar; 25(1):39-44. PubMed ID: 16761616
[TBL] [Abstract][Full Text] [Related]
4. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
[TBL] [Abstract][Full Text] [Related]
5. Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer.
Seo JH; Oh SC; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS; Kim AR; Lee JB; Koo BH
Cancer Chemother Pharmacol; 2007 Feb; 59(2):269-74. PubMed ID: 16763791
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
D'Agostino G; Amant F; Berteloot P; Scambia G; Vergote I
Gynecol Oncol; 2003 Mar; 88(3):266-9. PubMed ID: 12648573
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine in advanced breast cancer.
Possinger K
Anticancer Drugs; 1995 Dec; 6 Suppl 6():55-9. PubMed ID: 8718426
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
10. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment.
Suzuki Y; Tokuda Y; Fujiwara Y; Iwata H; Sasaki Y; Saji S; Aogi K; Nambu Y; Suri A; Saeki T; Takashima S
Jpn J Clin Oncol; 2009 Nov; 39(11):699-706. PubMed ID: 19776022
[TBL] [Abstract][Full Text] [Related]
14. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Alexopoulos A; Tryfonopoulos D; Karamouzis MV; Gerasimidis G; Karydas I; Kandilis K; Stavrakakis J; Stavrinides H; Georganta C; Ardavanis A; Rigatos G
Ann Oncol; 2004 Jan; 15(1):95-9. PubMed ID: 14679126
[TBL] [Abstract][Full Text] [Related]
15. Phase II activity of gemcitabine in advanced breast cancer.
Carmichael J; Walling J
Semin Oncol; 1996 Oct; 23(5 Suppl 10):77-81. PubMed ID: 8893887
[TBL] [Abstract][Full Text] [Related]
16. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study.
Kakolyris S; Kalbakis K; Potamianou A; Malamos N; Vamvakas L; Christophillakis C; Tselepatiotis E; Giassas S; Mavroudis D; Amarantidis K; Georgoulias V
Oncology; 2006; 70(4):273-9. PubMed ID: 17047398
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
Schmid P; Heilmann V; Schulz CO; Dieing A; Lehenbauer-Dehm S; Jehn C; Sezer O; Possinger K; Flath B
J Cancer Res Clin Oncol; 2005 Sep; 131(9):568-74. PubMed ID: 16044345
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]